July 23, 2020
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President, Global Medical Affairs, and the search was successfully completed in less than 60 days with the appointment of Dr. Christophe Hotermans. A seasoned medical affairs executive and industry veteran, Dr. Hotermans will lead the execution and development of worldwide medical strategies, activities, and operations as a member of the Akcea executive management team. Dr. Hotermans has 20+ years of experience, including more than 12 years in the biotechnology industry with roles in drug safety and medical affairs, both US and global. During this time, he launched five products across multiple therapeutic areas in specialty care and rare disease. His expertise in developing global medical strategies in these areas will be a great asset to Akcea as they continue to globally execute two commercial launches. The Chase Group appreciates a relational collaboration with the Akcea executive team and looks forward to the continued partnership as Akcea Therapeutics develops and commercializes products for patients living with serious and rare diseases.
To learn how The Chase Group can identify high caliber talent for your team, please contact karen@chasegroup.com.
